Abstract: Secondary hyperparathyroidism (SHPT) is a critical clinical manifestation of chronic kidney disease-mineral and bone disorder (CKD-MBD), significantly impacting the prognosis of maintenance hemodialysis patients. Calcimimetics activate the calcium-sensing receptor (CaSR), effectively reducing parathyroid hormone (PTH) levels without increasing the risks of hypercalcemia and vascular calcification. To standardize and optimize the use of calcimimetics in SHPT treatment, this consensus was developed through a systematic literature review, integrating with clinical practices and expert experiences in China, following the principles of ‘evidence-based first, consensus supplementary, experience as reference’. Utilizing the nominal group technique, 14 recommendations were established, covering the timing of drug administration, clinical efficacy, use in special populations, combination therapy, and clinical safety of calcimimetics in SHPT treatment. The consensus also provides detailed guidelines on the utilization, monitoring indicators, and management of adverse reactions of calcimimetics, providing scientific guidance for clinicians in various medical institutions to improve treatment outcomes and patient prognosis.

Key words: Calcimimetics, Maintenance hemodialysis, Secondary hyperparathyroidism, Parathyroid hormone